HomeComparePXJ vs ABBV

PXJ vs ABBV: Dividend Comparison 2026

PXJ yields 2.27% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $79.3K in total portfolio value
10 years
PXJ
PXJ
● Live price
2.27%
Share price
$41.46
Annual div
$0.94
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.0K
Annual income
$263.04
Full PXJ calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — PXJ vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPXJABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PXJ + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PXJ pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PXJ
Annual income on $10K today (after 15% tax)
$193.07/yr
After 10yr DRIP, annual income (after tax)
$223.58/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,832.42/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PXJ + ABBV for your $10,000?

PXJ: 50%ABBV: 50%
100% ABBV50/50100% PXJ
Portfolio after 10yr
$62.7K
Annual income
$12,517.40/yr
Blended yield
19.97%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

PXJ
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PXJ buys
0
ABBV buys
0
No recent congressional trades found for PXJ or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPXJABBV
Forward yield2.27%3.06%
Annual dividend / share$0.94$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$23.0K$102.3K
Annual income after 10y$263.04$24,771.77
Total dividends collected$2.5K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PXJ vs ABBV ($10,000, DRIP)

YearPXJ PortfolioPXJ Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,927$227.14$11,550$430.00$623.00ABBV
2$11,924$231.96$13,472$627.96$1.5KABBV
3$12,995$236.57$15,906$926.08$2.9KABBV
4$14,146$240.95$19,071$1,382.55$4.9KABBV
5$15,381$245.13$23,302$2,095.81$7.9KABBV
6$16,707$249.10$29,150$3,237.93$12.4KABBV
7$18,129$252.87$37,536$5,121.41$19.4KABBV
8$19,655$256.44$50,079$8,338.38$30.4KABBV
9$21,291$259.83$69,753$14,065.80$48.5KABBV
10$23,044$263.04$102,337$24,771.77$79.3KABBV

PXJ vs ABBV: Complete Analysis 2026

PXJStock

The Invesco Oil & Gas Services ETF (Fund) is based on the Dynamic Oil Services Intellidex Index (Index). The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Index. The Index thoroughly evaluates companies based on a variety of investment merit criteria, including: price momentum, earnings momentum, quality, management action, and value. The Index is composed of stocks of 30 U.S. companies that assist in the production, processing and distribution of oil and gas. The Index may include companies that are engaged in the drilling of oil and gas wells; manufacturing oil and gas field machinery and equipment; or providing services to the oil and gas industry, such as well analysis, platform and pipeline engineering and construction, logistics and transportation services, oil and gas well emergency management and geophysical data acquisition and processing. The Fund and the Index are rebalanced and reconstituted quarterly in February, May, August and November.

Full PXJ Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this PXJ vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PXJ vs SCHDPXJ vs JEPIPXJ vs OPXJ vs KOPXJ vs MAINPXJ vs JNJPXJ vs MRKPXJ vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.